bioXXmed AG Inhaber-Aktien o.N.
- BID
0.83
- ASK
0.85
- 100 Units2 Units
- 07/21, 12:51:01 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
-
Market Cap
85,421
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.54 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.83 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 12:48:58 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.83 | 0.83 |
| PREV. DAY'S PRICE | 0.85 | (07/20) |
| CHANGE DAY BEFORE | -0.02 | -2.35 % |
| 52 WEEK HIGH / LOW | (-) | (-) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -172.99 | -4.20 | -1.54 | - | - |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 4.71 | 4.68 | - | - | - |
PRICE - SALES RATIO | 127.26 | 426.73 | 1.56 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A41YD3 |
| ISIN | DE000A41YD32 |
| SYMBOL | T5O |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | BIOXXMED AG INH O.N. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 100,495 |
| MARKET CAPITALISATION | 85,421 |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -20.53 % | -25.00 % | -44.95 % | 0.00 % | - | - | - | - |
| HIGH | 0.95 | 0.95 | 1.10 | 1.60 | - | - | - | - |
| LOW | 0.60 | 0.60 | 0.60 | 0.60 | - | - | - | - |
Dividende
pro Aktie
BIOXXMED AG INH O.N. does not deliver dividend information
Company profile
bioXXmed AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company provides treatment options in dermatology, cardiology and angiology, urology, and oncology. Its products and pipeline include DermaPro, CardioClean, Cancer T17-n, and Utisept. The company was founded by Dirk Kaiser and Mark-Andre Freyberg in 2000 and is headquartered in Darmstadt, Germany.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.